CVS Lifts 2025 Adjusted EPS Forecast Again: What's Driving the Move?

CVS Health reported its Q2 2025 results, notably raising its full-year 2025 adjusted EPS forecast for the second time to $6.30-$6.40. This upward revision is driven by strong segment performance, including a 39.4% adjusted operating income increase in Health Care Benefits and 7.6% in Pharmacy & Consumer Wellness, alongside robust Medicare strength and high PBM retention rates. The positive outlook underscores the benefits of CVS's diversified model and strategic initiatives, contributing to its recent stock outperformance against industry peers.

Analysis

CVS Health demonstrates robust operational strength and an improved outlook, underscored by its second upward revision of the full-year 2025 adjusted EPS forecast to a range of $6.30-$6.40. This optimism is fueled by solid Q2 2025 results, where adjusted operating income (AOI) grew 2% year-over-year, driven by a significant 39.4% AOI increase in the Health Care Benefits segment and a 7.6% rise in Pharmacy & Consumer Wellness. While adjusted EPS saw a minor decline to $1.81, the company's diversified model is proving effective. Key drivers include progress on Aetna's margin recovery, strength in Medicare, and a stable Caremark PBM business maintaining a high retention rate of around 90%. A notable headwind is the incremental pressure in the Health Care Delivery segment from higher medical benefit ratios at Oak Street, which management is actively addressing. From a market perspective, the stock has substantially outperformed its peers, rising 13.2% in the past six months against a 10.8% industry decline, yet it trades at a discounted forward P/E of 9.14 compared to the industry average of 13.93. This positive momentum is further corroborated by recent upward analyst estimate revisions for 2025 and 2026.

Key Decisions for Investors

• Given the strong operational performance, raised full-year guidance, and a significant valuation discount with a forward P/E of 9.14 versus the industry's 13.93, the stock presents a compelling value case.
• Investors should closely monitor the Health Care Delivery segment, as persistent pressure from high medical benefit ratios at Oak Street remains a key risk that could temper the positive performance in other divisions.
• The stock's relative strength and positive analyst revisions are supportive, but continued execution on Aetna's margin recovery and stabilization of the Oak Street business are critical catalysts for a potential re-rating toward the industry's average multiple.